Liver transplantation in patients with hepatocellular carcinoma Piotr Małkowski, Dariusz Wasiak, Jarosław Czerwiński, Marek Pacholczyk, Beata Łągiewska Medical Science Review - Hepatologia 2008; 8 106-108 aaICID: 862392
Article type: Review article
IC™ Value: 3.01
Abstract provided by Publisher
Hepatocellular carcinoma (HCC) is one of the most commonly occurring solid tumors worldwide and is the most frequent of cancer death in some parts of the world (China, Africa). The incidence of HCC appears to be rising in developed western countries as well. The most frequent underlying factors causing HCC are chronic viral hepatitis and cirrhosis. The authors present the current status of liver transplantation (LTx) in patients with HCC, as well another methods of treatment which can be used in patients waiting for LTx. Because of organ shortage the dropout rate from waiting list for LTx among patients with HCC is high, mostly due to tumor progression. The role of new strategies introduced to the treatment of HCC patients e.g. multi-modality therapy prior to transplantation, the priority in MELD system for HCC patients or genetic studies of the tumor, in reduction of dropout rate from waiting list and decreased of tumor recurrence rate, are discussed.